A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
12actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-05 | actual | When the study began enrolling |
| Primary completion | 2025-10-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-29 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: PF-08049820 MR1
- Drug: PF-08049820 MR2
- Drug: PF-08049820 IR
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Plasma Area Under the Concentration Versus Time Curve (AUC) of PF-08049820 in the fasted state
measured Pre-dose until 72 hours post dose
PK: Plasma Maximum Concentration (Cmax) of PF-08049820 in the fasted state
measured Pre-dose until 72 hours post dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed